ReviewDrugs2009
Management of newly diagnosed epilepsy: a practical guide to monotherapy.
Review in Drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Surgery for pediatric drug resistant epilepsy: a narrative review of its history, surgical implications, and treatment strategies.Translational pediatrics · 2023Review
- The Interconnected Mechanisms of Oxidative Stress and Neuroinflammation in Epilepsy.Antioxidants (Basel, Switzerland) · 2022Review
- Review
- Efficacy and Safety of Levetiracetam and Carbamazepine as Monotherapy in Partial Seizures.Epilepsy research and treatment · 2015Article
- Zonisamide: a review of its use as adjunctive therapy in the management of partial seizures in pediatric patients aged ≥6 years.Paediatric drugs · 2014Review
- Lacosamide: a review of its use as adjunctive therapy in the management of partial-onset seizures.CNS drugs · 2013Review
- Review
- Levetiracetam: a review of its use in epilepsy.Drugs · 2011Review
- Prescription pattern of antiepileptic drugs in a tertiary care center of India.Indian journal of pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the emergence of several new antiepileptic drugs (AEDs) in recent years, choosing an agent to initiate monotherapy in newly diagnosed epilepsy has become increasingly complicated. We provide a succinct guide intended for general clinicians to assist in this clinical situation. General features of AEDs, differences between first- and second-generation drugs, and characteristics specific to each medication are discussed. The emphasis is on tailoring treatment to the individual patient with epilepsy because each case has specific features that must be accounted for, including the type of seizure and epilepsy, medication-specific characteristics, co-morbid conditions, drug-drug interactions, patient drug tolerance, and special population factors, all of which must be balanced and optimized when choosing initial therapy in this setting. Finally, this information is conveniently summarized in a set of tables and illustrated by way of case scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.